MX367671B - Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis. - Google Patents

Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis.

Info

Publication number
MX367671B
MX367671B MX2014009464A MX2014009464A MX367671B MX 367671 B MX367671 B MX 367671B MX 2014009464 A MX2014009464 A MX 2014009464A MX 2014009464 A MX2014009464 A MX 2014009464A MX 367671 B MX367671 B MX 367671B
Authority
MX
Mexico
Prior art keywords
enuresis
treatment
pharmaceutical composition
composition
urinary incontinence
Prior art date
Application number
MX2014009464A
Other languages
English (en)
Other versions
MX2014009464A (es
Inventor
Carlos Llobregat Agusti Juan
Original Assignee
Laboratec S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratec S L filed Critical Laboratec S L
Publication of MX2014009464A publication Critical patent/MX2014009464A/es
Publication of MX367671B publication Critical patent/MX367671B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3486—Humulus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para tratamiento de incontinencia urinaria y/o enuresis que comprende al menos una mezcla de flavonoides entre el 0,5% - 20% en peso, de taninos condensados o proantocianidinas entre el 2% - 20% en peso y de ácido Gamma-aminobutírico (GABA) entre el 0,3% - 60% en peso, sobre el total de la composición. Dicha composición adicionalmente comprende al menos 50% de un extracto de Humulus lupulus. La presente invención también se refiere al uso de dicha composición para la obtención de un medicamento para tratar la incontinencia y/o enuresis, particularmente la enuresis en niños, así como en adultos o ancianos que tienen pérdidas de orina como la incontinencia de estrés o de urgencia.
MX2014009464A 2012-02-15 2013-01-22 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis. MX367671B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201230242A ES2423254B1 (es) 2012-02-15 2012-02-15 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis
PCT/ES2013/070022 WO2013121061A1 (es) 2012-02-15 2013-01-22 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis

Publications (2)

Publication Number Publication Date
MX2014009464A MX2014009464A (es) 2014-11-12
MX367671B true MX367671B (es) 2019-08-30

Family

ID=48983578

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009464A MX367671B (es) 2012-02-15 2013-01-22 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis.

Country Status (20)

Country Link
US (1) US9272011B2 (es)
EP (1) EP2815755A4 (es)
JP (1) JP6203761B2 (es)
KR (1) KR20140127874A (es)
CN (1) CN104254338B (es)
AU (1) AU2013220284A1 (es)
BR (1) BR112014020154A8 (es)
CA (1) CA2864426A1 (es)
CL (1) CL2014002128A1 (es)
CO (1) CO7141408A2 (es)
CR (1) CR20140419A (es)
EA (1) EA028184B1 (es)
ES (1) ES2423254B1 (es)
IL (1) IL233978A0 (es)
MA (1) MA37324A1 (es)
MX (1) MX367671B (es)
PE (1) PE20142324A1 (es)
PH (1) PH12014501823A1 (es)
WO (1) WO2013121061A1 (es)
ZA (1) ZA201406668B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110339316B (zh) * 2019-08-09 2021-09-21 河南中医药大学 一种治疗中风后尿失禁的中药
CN116036153B (zh) * 2023-02-22 2023-09-26 深圳市儿童医院 啤酒花提取物在制备用于治疗或者预防抑郁症、抑郁症并发症、焦虑症的产品中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9137091A (en) 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
ES2165857T3 (es) 1992-05-20 2002-04-01 Univ Northwestern Analogos de gaba y acido l-glutamico para el tratamiento de trastornos del sistema nervioso central.
ES2313880T3 (es) * 1999-04-08 2009-03-16 Warner-Lambert Company Llc Procedimiento para el tratamiento de la icontinencia.
FR2823672B1 (fr) * 2001-04-23 2004-03-12 Berkem Sa Extraits de houblon et leur utilisation dans la preparation d'un medicament ayant des proprietes oestrogenes
JP2003088335A (ja) * 2001-09-14 2003-03-25 Pharmafoods Kenkyusho:Kk 排尿機能改善用食品組成物及びそれを含有する飲食品
GB0306568D0 (en) * 2003-03-21 2003-04-30 Unilever Plc Compositions of natural products and use thereof
NZ526350A (en) * 2003-06-09 2004-10-29 A Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcohol
CN1867327A (zh) * 2003-09-11 2006-11-22 什诺波特有限公司 使用gaba类似物的前药治疗和/或预防尿失禁
KR101135824B1 (ko) * 2003-10-09 2012-04-16 퍼시픽 애로우 리미티드 잔토세라스 소르비폴리아 추출물을 포함하는 조성물,이로부터 단리된 화합물, 이의 제조방법 및 이의 용도
US20070116839A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith
EP1889612A3 (en) * 2006-07-24 2008-03-19 Jan Kees Piet Bruinstroop Method for controlling micturition
US20090180999A1 (en) * 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition

Also Published As

Publication number Publication date
US20150044308A1 (en) 2015-02-12
JP6203761B2 (ja) 2017-09-27
WO2013121061A1 (es) 2013-08-22
CL2014002128A1 (es) 2015-03-13
BR112014020154A8 (pt) 2017-07-11
PH12014501823A1 (en) 2014-11-24
IL233978A0 (en) 2014-09-30
EP2815755A4 (en) 2015-08-05
AU2013220284A1 (en) 2014-09-25
US9272011B2 (en) 2016-03-01
CA2864426A1 (en) 2013-08-22
PE20142324A1 (es) 2015-01-16
BR112014020154A2 (es) 2017-06-20
EA028184B1 (ru) 2017-10-31
KR20140127874A (ko) 2014-11-04
CN104254338A (zh) 2014-12-31
JP2015507002A (ja) 2015-03-05
MX2014009464A (es) 2014-11-12
CN104254338B (zh) 2019-05-31
MA37324A1 (fr) 2016-03-31
EA201491437A1 (ru) 2015-06-30
ES2423254A1 (es) 2013-09-18
EP2815755A1 (en) 2014-12-24
CO7141408A2 (es) 2014-12-12
CR20140419A (es) 2014-11-28
ES2423254B1 (es) 2014-03-26
ZA201406668B (en) 2016-05-25

Similar Documents

Publication Publication Date Title
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
UY32497A (es) "2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso"
MX367097B (es) FORMULACION PARA ANTICUERPO ANTI-A4ß7.
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
ECSP13012473A (es) Forma de dosificación resistente a alteración que comprende un polímero aniónico
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CO6460769A2 (es) Inhibidores de la replicación viral novedosos
MX383317B (es) FORMULACIÓN PARA ANTICUERPO ANTI-A4ß7.
CU24065B1 (es) Forma de dosificación farmacéutica que comprende nifedipino y un antagonista de angiotensina ii
AR080295A1 (es) Composiciones para el cuidado bucal y metodos de tratamiento
CO6710926A2 (es) Compuestos de n-heteroarilo
BR112012012862A2 (pt) composição farmacêutica compreendendo oligopeptídeos
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".
MX347927B (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
BRPI1006849B8 (pt) composição compreendendo extratos lipofílicos de zingiber officinale e echinacea angustifolia e seu uso na preparação de um medicamento para prevenção e tratamento de refluxo esofágico
CL2012002893A1 (es) Composición de al menos un ingrediente activo de origen vegetal o sintético análogo del mismo, o extracto de origen vegetal que lo contiene, en una solución acuosa, que además comprende lecitina como agente encapsulante; medicamento que la comprende; método para su preparación; y su uso para tratar parasitosis intestinales.
CO7141408A2 (es) Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
AR087878A1 (es) Extractos de cynara scolymus para el tratamiento de la dislipidemia
WO2011027344A3 (en) Combination of vitamin e and beta-glycosphingolipids in compositions and methods for preventing and treating hepatic disorders
BR112015023872A2 (pt) composição compreendendo arabinogalactano e poliofenóis de árvores de lariço
GT200900295A (es) Composición farmacéutica que comprende la combinación del agente antimicrobiano ciprofloxacino y el agente antioxidante ácido ascórbico para el tratamiento de infecciones urinarias.
CL2012003434A1 (es) Composicion dermatologica que comprende una combinacion de: 0,1-1% de oxido de cobre; 0,1-1% de oxido de zinc; 0,1-2% de extracto de calendula ( calenduls spp) y entre 0,1-2% de extracto de matico ( buddleja globosa); uso en el tratamiento y prevencion de afecciones en la pie.

Legal Events

Date Code Title Description
FG Grant or registration